ArticleCureus2025
Atrial Fibrillation at Hassan II Regional Hospital, Agadir, Morocco: Insights Into Presentation and Management.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Atrial fibrillation (AF) is a common supraventricular arrhythmia marked by chaotic, uncoordinated atrial activity that impairs effective contraction. This hemodynamic inefficiency promotes intracardiac thrombus formation, making AF a major cause of ischemic cerebral events and other embolic events. Objectives The objective of our study is to describe the epidemiological, clinical, paraclinical, etiological, therapeutic characteristics, and outcomes of AF at Hassan II Regional Hospital in Agadir, Morocco and to compare findings with the available literature. Methods Our study consisted of a cross-sectional, retrospective, observational study including 111 patients hospitalized for AF in the Cardiology Department of Hassan II Regional Hospital Center (Agadir) over two years (June 1, 2021, to June 1, 2023). Descriptive analyses were performed using the Excel program. Results Our cohort included a total of 111 patients, with a male-to-female ratio of 0.94. The mean age was 63.2 years old. Diabetes and hypertension were the most prevalent risk factors (each 29.7%), and pre-existing heart disease was present in 63%, predominantly ischemic heart disease. Dyspnea was the leading presentation (81.1%). On admission, the mean heart rate was 117 beats per minute (bpm), and clinical signs of heart failure were observed in 71.1%. Electrocardiography showed left bundle branch block in 25.2% and signs of left ventricular hypertrophy in 27%; and chest imaging showed cardiomegaly in 59.5%. Transthoracic echocardiography revealed left atrial dilation in 71.2%, impaired left ventricular systolic function in 55%, and severe mitral stenosis in 17.1%. AF was valvular in 22.5%, while ischemic heart disease was the leading etiology (28.8%). A permanent AF pattern predominated (75.7%). Anticoagulation, guided by thromboembolic risk, was initiated in 90.1% of patients, with vitamin K antagonists (VKAs) used in 62.1%. Rhythm control was chosen in 18.9% versus rate control in 81.1%. The mean hospital stay was 10.3 days, and outcomes were favorable in 70.2%. Conclusion AF at Hassan II Regional Hospital in Agadir, Morocco, is characterized by a high comorbidity burden, frequent heart failure at presentation, substantial structural heart disease, and predominance of permanent AF. Anticoagulation was instituted in most patients, with rate control as the primary strategy. These findings underscore the need to strengthen early detection and optimize evidence-based management to prevent severe complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.